- Trials with a EudraCT protocol (852)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
852 result(s) found for: Rheumatoid Arthritis AND Arthritis.
Displaying page 11 of 43.
EudraCT Number: 2007-000828-40 | Sponsor Protocol Number: C87076 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) AT (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004000-35 | Sponsor Protocol Number: DRI13926 | Start Date*: 2017-02-24 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenil... | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) EE (Prematurely Ended) FI (Trial now transitioned) CZ (Completed) PL (Completed) NL (Ongoing) Outside EU/EEA BG (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011206-42 | Sponsor Protocol Number: INCB 28050-201 | Start Date*: 2009-08-18 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... | |||||||||||||
Medical condition: Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004631-22 | Sponsor Protocol Number: TapERA2012 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:University Hospitals Leuven | |||||||||||||
Full Title: TapERA: Maintaining remission in RA while tapering Etanercept. | |||||||||||||
Medical condition: reumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002339-27 | Sponsor Protocol Number: I4V-MC-JADX | Start Date*: 2013-01-14 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying A... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) IT (Completed) PT (Completed) GB (Completed) CZ (Completed) SK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019935-37 | Sponsor Protocol Number: ML25346 | Start Date*: 2010-09-15 | |||||||||||
Sponsor Name:Roche Oy | |||||||||||||
Full Title: A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practi... | |||||||||||||
Medical condition: Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019438-28 | Sponsor Protocol Number: 2010-019438-28 | Start Date*: 2010-05-17 | ||||||||||||||||||||||||||
Sponsor Name:Mälarsjukhuset Eskilstuna | ||||||||||||||||||||||||||||
Full Title: Vaccination against TBE in patients who use immunosuppressive drugs | ||||||||||||||||||||||||||||
Medical condition: TBE vaccin in patients using immunosuppressive drugs | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005096-12 | Sponsor Protocol Number: OPRERA | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad, öppen, non-inferiority klinisk studie | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001105-42 | Sponsor Protocol Number: H9B-MC-BCDG | Start Date*: 2008-09-16 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibit... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023692-26 | Sponsor Protocol Number: D4300C00004 | Start Date*: 2011-04-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005759-41 | Sponsor Protocol Number: WA20496 | Start Date*: 2008-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011000-34 | Sponsor Protocol Number: CAIN457F2201 | Start Date*: 2009-09-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an exten... | |||||||||||||
Medical condition: Moderate to severe Rheumatoid Arthritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BE (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002629-30 | Sponsor Protocol Number: CDP870-051 | Start Date*: 2006-01-30 | |||||||||||
Sponsor Name:UCB Inc | |||||||||||||
Full Title: A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptom... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005427-28 | Sponsor Protocol Number: C87094 | Start Date*: 2009-04-22 | |||||||||||
Sponsor Name:UCB Pharma SA | |||||||||||||
Full Title: A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab peg... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007185-33 | Sponsor Protocol Number: 3242K1-2000-WW | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
Full Title: A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BE (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022243-38 | Sponsor Protocol Number: CNTO136ARA3003 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) GB (Completed) AT (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002846-36 | Sponsor Protocol Number: A3921019 | Start Date*: 2005-06-14 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000609-58 | Sponsor Protocol Number: NN8226-3612 | Start Date*: 2013-02-20 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021449-28 | Sponsor Protocol Number: PHRI10 – DM – AFORA | Start Date*: 2010-10-04 | |||||||||||
Sponsor Name:CHRU de TOURS | |||||||||||||
Full Title: Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde | |||||||||||||
Medical condition: Polyarthrite rhumatoïde | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004398-16 | Sponsor Protocol Number: W10-046 | Start Date*: 2008-10-08 | |||||||||||
Sponsor Name:Abbott Scandinavia AB | |||||||||||||
Full Title: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission | |||||||||||||
Medical condition: Adalimumab has the indication for life-long treatment of RA but can adalimumab be discontinued in patients who are in stable clinical remission (DAS28<2.6) with retained low disease activity or wil... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
